This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.